April 11, 2025

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex,Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/ Madam,

Sub: Completion of US FDA Inspection at Raleigh Plant, North Carolina, owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the Company

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform that:

The United States Food and Drug Administration (USFDA) has conducted an inspection at Raleigh Plant, North Carolina, USA, owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the Company, established for manufacturing Inhalers and Derma products, from March 24, 2025 to April 10, 2025.

The inspection was completed on April 10, 2025 and at the conclusion, the USFDA issued a Form 483 with 11 observations. These observations are procedural in nature.

We will submit a comprehensive response to the USFDA within the stipulated timeline, addressing each observation with appropriate corrective and preventive actions. The Company is committed to maintaining the highest standards of quality and compliance across all its operations.

We do not expect this development to have any material impact on the current business operations or existing supplies from this facility.

We will keep the stock exchanges informed if there is any further information relating to the above in the future.

This disclosure is also provided in the prescribed format as **Annexure.**

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

Digitally signed by BADDIGAM ADI REDDY
Date: 2025.04.11 14:23:31 +05'30'

B. Adi Reddy
Company Secretary

Annexure

S.No	Particulars	Details
1.	Name of the authority	U.S. Food and Drug Administration (US FDA), USA
2.	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	The United States Food and Drug Administration (USFDA) has conducted an inspection at Raleigh Plant, North Carolina, USA, owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the Company, established for manufacturing Inhalers and Derma products, from March 24, 2025 to April 10, 2025. The inspection was completed on April 10, 2025 and at the conclusion, the USFDA issued a Form 483 with 11 observations. These observations are procedural in nature.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	April 11, 2025
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	The inspection was completed on April 10, 2025 and at the conclusion, the USFDA issued a Form 483 with 11 observations. These observations are procedural in nature. We will submit a comprehensive response to the USFDA within the stipulated timeline, addressing each observation with appropriate corrective and preventive actions. The Company is committed to maintaining the highest standards of quality and compliance across all its operations.
5.	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	We do not expect this development to have any material impact on the current business operations or existing supplies from this facility.

Digitally signed by BADDIGAM ADI REDDY
Date: 2025.04.11 14:23:58 +05'30'